دورية أكاديمية
Kaposi sarcoma-associated herpesvirus (KSHV) seroprevalence in population-based samples of African children: evidence for at least 2 patterns of KSHV transmission.
| العنوان: | Kaposi sarcoma-associated herpesvirus (KSHV) seroprevalence in population-based samples of African children: evidence for at least 2 patterns of KSHV transmission. |
|---|---|
| المؤلفون: | Butler LM; University of California, San Francisco, 50 Beale St., Suite 120, San Francisco, California 94105, USA. lbutler@psg.ucsf.edu, Dorsey G, Hladik W, Rosenthal PJ, Brander C, Neilands TB, Mbisa G, Whitby D, Kiepiela P, Mosam A, Mzolo S, Dollard SC, Martin JN |
| المصدر: | The Journal of infectious diseases [J Infect Dis] 2009 Aug 01; Vol. 200 (3), pp. 430-8. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Oxford University Press Country of Publication: United States NLM ID: 0413675 Publication Model: Print Cited Medium: Print ISSN: 0022-1899 (Print) Linking ISSN: 00221899 NLM ISO Abbreviation: J Infect Dis Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Jan. 2011- : Oxford : Oxford University Press Original Publication: 1904-2010 : Chicago, IL : University of Chicago Press |
| مواضيع طبية MeSH: | Herpesviridae Infections/*epidemiology , Herpesviridae Infections/*transmission , Herpesvirus 8, Human/*immunology, Age Distribution ; Antibodies, Viral/blood ; Child ; Child, Preschool ; Female ; Herpesviridae Infections/blood ; Herpesvirus 8, Human/isolation & purification ; Humans ; Infant ; Male ; Seroepidemiologic Studies ; Sex Distribution ; South Africa/epidemiology ; Uganda/epidemiology |
| مستخلص: | Background: Kaposi sarcoma-associated herpesvirus (KSHV) infection is endemic among adult populations in Africa. A prevailing view is that childhood transmission is primarily responsible for the high seroprevalence of KSHV among adults that is observed throughout the continent. However, few studies have directly examined children, particularly in locations where KS is not commonly endemic. Methods: Participants were children aged 1.5-8.9 years, including 427 children from a population-based sample in South Africa, 422 from a population-based sample in Uganda, and 567 from a clinic-based sample in Uganda. All serum specimens were tested by the same laboratory for KSHV antibodies with use of 2 enzyme immunoassays (against K8.1 and ORF65) and 1 immunofluorescence assay. Results: KSHV seroprevalence was 7.5%-9.0% among South African children and was not associated with age. In contrast, in the Ugandan population-based sample, KSHV seroprevalence increased from 10% among 2-year-old children to 30.6% among 8-year-old children (P(trend) < .001). In the Ugandan clinic-based sample, seroprevalence increased from 9.3% among 2-year-old children to 36.4% among 8-year-old children (P(trend) < .001). Conclusion: Two distinct relationships between age and KSHV infection among children imply that KSHV transmission among children is not uniform throughout Africa and is therefore not always responsible for the high seroprevalence observed in adults. There are at least 2 patterns of KSHV transmission in Africa. |
| References: | Biometrics. 1986 Mar;42(1):121-30. (PMID: 3719049) AIDS. 1998 Dec 24;12(18):2481-8. (PMID: 9875587) Int J Dermatol. 2006 Apr;45(4):381-3. (PMID: 16650162) J Acquir Immune Defic Syndr. 2003 Jun 1;33(2):206-10. (PMID: 12794556) J Clin Virol. 2004 Jun;30(2):137-44. (PMID: 15125869) J Infect Dis. 2007 Mar 15;195(6):809-16. (PMID: 17299710) J Acquir Immune Defic Syndr. 2007 Mar 1;44(3):351-5. (PMID: 17195763) AIDS. 2002 Oct 18;16(15):2073-8. (PMID: 12370507) Pediatr Infect Dis J. 1999 Sep;18(9):795-9. (PMID: 10493340) AIDS. 2002 Dec 6;16(18):2473-8. (PMID: 12461423) Lancet. 1995 Sep 23;346(8978):799-802. (PMID: 7674745) Br J Cancer. 1998 Dec;78(11):1521-8. (PMID: 9836488) J Acquir Immune Defic Syndr. 2005 Apr 1;38(4):474-9. (PMID: 15764964) Cancer Res. 2004 Dec 1;64(23):8782-7. (PMID: 15574792) Virology. 1998 Mar 30;243(1):208-17. (PMID: 9527930) Eur J Epidemiol. 2001;17(9):871-6. (PMID: 12081107) J Med Virol. 2004 Jan;72(1):126-31. (PMID: 14635020) Transfusion. 2003 Sep;43(9):1260-8. (PMID: 12919429) J Infect Dis. 1998 Aug;178(2):304-9. (PMID: 9697708) J Infect Dis. 2004 Jul 1;190(1):199-200; author reply 200-1. (PMID: 15195261) Int J Cancer. 1999 Apr 12;81(2):189-92. (PMID: 10188717) Int J Cancer. 1998 Aug 12;77(4):543-8. (PMID: 9679756) JAMA. 1997 Feb 12;277(6):478-81. (PMID: 9020272) AIDS. 2003 Aug 15;17(12):1717-30. (PMID: 12891058) AIDS. 2008 Feb 19;22(4):519-26. (PMID: 18301065) Sex Transm Dis. 2001 Feb;28(2):77-81. (PMID: 11234789) Int J Cancer. 2001 Dec 1;94(5):749-52. (PMID: 11745472) J Infect Dis. 2003 Jun 15;187(12):1944-50. (PMID: 12792871) Int J Cancer. 2007 Jan 15;120(2):321-8. (PMID: 17066452) J Infect Dis. 2003 Jun 1;187(11):1780-5. (PMID: 12751036) J Clin Microbiol. 1998 Jun;36(6):1574-7. (PMID: 9620379) Malar J. 2006 Mar 21;5:18. (PMID: 16551365) J Gen Virol. 2001 Oct;82(Pt 10):2393-2404. (PMID: 11562533) J Infect Dis. 2004 Sep 15;190(6):1068-75. (PMID: 15319855) JAMA. 2002 Mar 13;287(10):1295-300. (PMID: 11886321) Am J Epidemiol. 2008 Aug 1;168(3):311-20. (PMID: 18515794) J Infect Dis. 1999 Sep;180(3):600-6. (PMID: 10438345) J Infect Dis. 1999 Oct;180(4):1010-7. (PMID: 10479125) N Engl J Med. 2006 Sep 28;355(13):1331-8. (PMID: 17005950) J Natl Cancer Inst. 2003 Sep 3;95(17):1330-5. (PMID: 12953087) N Engl J Med. 1998 Apr 2;338(14):948-54. (PMID: 9521982) Transfusion. 1998 Aug;38(8):771-5. (PMID: 9709786) N Engl J Med. 1996 Jul 25;335(4):233-41. (PMID: 8657239) J Clin Virol. 1999 Dec;14(3):167-72. (PMID: 10614853) Semin Cancer Biol. 1999 Jun;9(3):187-99. (PMID: 10343070) JAMA. 1998 Jul 1;280(1):31-2. (PMID: 9660357) J Infect Dis. 2009 Jun 1;199(11):1592-8. (PMID: 19385734) Science. 1994 Dec 16;266(5192):1865-9. (PMID: 7997879) Int J Cancer. 1998 Sep 11;77(6):817-20. (PMID: 9714046) Transfusion. 2005 Apr;45(4):500-3. (PMID: 15819669) |
| معلومات مُعتمدة: | T32 MH019105 United States MH NIMH NIH HHS; K01 HD052020-03 United States HD NICHD NIH HHS; HHSN261200800001C United States CA NCI NIH HHS; K01 HD052020 United States HD NICHD NIH HHS; U01 AI052142 United States AI NIAID NIH HHS; HHSN261200800001E United States CA NCI NIH HHS; P30 AI027763 United States AI NIAID NIH HHS; R01 CA119903 United States CA NCI NIH HHS |
| المشرفين على المادة: | 0 (Antibodies, Viral) |
| تواريخ الأحداث: | Date Created: 20090619 Date Completed: 20090925 Latest Revision: 20240615 |
| رمز التحديث: | 20240615 |
| مُعرف محوري في PubMed: | PMC3975590 |
| DOI: | 10.1086/600103 |
| PMID: | 19534596 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 0022-1899 |
|---|---|
| DOI: | 10.1086/600103 |